Previous Close | 19.20 |
Open | 19.14 |
Bid | 7.56 x 800 |
Ask | 21.12 x 800 |
Day's Range | 18.77 - 19.44 |
52 Week Range | 14.04 - 22.89 |
Volume | |
Avg. Volume | 291,885 |
Market Cap | 641.573M |
Beta (5Y Monthly) | 0.88 |
PE Ratio (TTM) | 16.94 |
EPS (TTM) | 1.11 |
Earnings Date | Nov 02, 2022 - Nov 07, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 32.80 |
Subscribe to Yahoo Finance Plus to view Fair Value for COLL
Last week, Collegium Pharmaceutical Inc (NASDAQ: COLL) reported Q2 results—the first full quarter with BioDelivery—and beat revenue and EBITDA estimates. HC Wainwright has downgraded the stock to Neutral with no price target vs. prior Buy with a $29 target. "We applaud the recent financial results but have been disappointed by Xtampza and Belbuca Rx trends, which are below our projections, down slightly Y/Y, and trajectories currently flat at best," the analyst writes. The analyst believes that
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -90.08% and 0.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
– Generated Record Net Revenue of $123.5 Million – – BDSI Integration Complete; On Track to Exceed Targeted Run Rate Synergies of at Least $75 Million – – Raises Full Year Adjusted EBITDA Guidance – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today reported its financial results for the quarter ended June 30, 2022 and provided a c